Dual PD-1/CTLA-4 Immunotherapy Shows Promise in Ovarian Cancer Treatment
核心洞察
Dual immune checkpoint inhibition targeting both PD-1 (搜索) and CTLA-4 (搜索) pathways demonstrates enhanced therapeutic efficacy compared to single-agent immunotherapy in ovarian cancer (搜索), with combination treatments achieving objective response rates of 31.4% versus 12.2% for monotherapy.
Novel bispecific antibodies like cadonilimab (AK104) that simultaneously target PD-1 (搜索) and CTLA-4 (搜索) show promising clinical activity in advanced ovarian cancer (搜索), achieving 94.1% objective response rates and 66.7% R0 resection rates when combined with neoadjuvant chemotherapy.
Combination of dual checkpoint inhibitors with cytokine-induced killer (CIK) cells significantly enhances anti-tumor effects by promoting apoptosis, inducing cell cycle arrest, and suppressing metastatic potential in ovarian cancer (搜索) cell lines.
Ovarian cancer (搜索) remains one of the most lethal gynecologic malignancies, with approximately 70% of patients diagnosed at advanced stages and overall 5-year survival rates around 40%. While immune checkpoint inhibitors (ICIs) have transformed treatment paradigms across multiple cancer types, their efficacy in ovarian cancer has been limited due to the disease's immunologically "cold" tumor phenotype characterized by low mutational burden and an immunosuppressive tumor microenvironment.
Dual Checkpoint Blockade Emerges as Promising Strategy
Recent clinical trials have demonstrated that combining PD-1 (搜索) and CTLA-4 (搜索) inhibitors may overcome some of the resistance mechanisms inherent to ovarian cancer (搜索). The NRG GY003 study, involving 100 patients with recurrent ovarian cancer, showed that nivolumab plus ipilimumab significantly improved objective response rates compared to nivolumab monotherapy (31.4% vs 12.2%, P = 0.034) and median progression-free survival (3.9 vs 2.0 months; HR = 0.53, P = 0.004).
The mechanistic rationale for dual checkpoint blockade lies in the complementary pathways targeted by these agents. CTLA-4 (搜索) primarily modulates CD4+ T cell activation and migration by regulating antigen-presenting cell-mediated CD28-B7 interactions, while PD-1 (搜索) acts downstream of T cell receptor signaling to reverse CD8+ T cell exhaustion without affecting clonal expansion.
Novel Bispecific Antibodies Show Clinical Promise
Cadonilimab (AK104), a tetravalent bispecific antibody targeting both PD-1 (搜索) and CTLA-4 (搜索), has demonstrated enhanced tumor-targeting capability through its unique structural design. In a phase II trial (NCT05430906) evaluating cadonilimab combined with neoadjuvant chemotherapy in advanced ovarian cancer (搜索), the regimen achieved impressive results among 17 enrolled patients: an R0 resection rate of 66.7%, objective response rate of 94.1% (including 1 complete and 15 partial responses), and pathological complete response rate of 11.8%.
Treatment-related adverse events occurred in 76.5% of patients, primarily thyroid dysfunction (23.5%) and myelosuppression (17.6%), with grade ≥3 events observed in 17.6% of cases. Notably, all adverse events were manageable, suggesting a favorable safety profile for this novel approach.
Neoadjuvant Applications Show Encouraging Results
The innovative KGOG 3046/TRUD study explored dual immunotherapy-chemotherapy approaches in the neoadjuvant setting. The 2025 final analysis of 45 patients stratified into multiple low-dose (n=23) and single high-dose (n=22) cohorts revealed superior outcomes in the multiple low-dose group for objective response rate (95.7% vs 77.3%, P = 0.048), chemotherapy response score grade 3 response (39.1% vs 22.7%), and pathological complete response rates (17.4% vs 4.6%).
The entire cohort maintained 65.9% 12-month and 36.4% 30-month progression-free survival rates. Comprehensive biomarker analysis identified predictive potential for PD-L1 (搜索) expression, mutational signature 3, and extracellular matrix components, providing critical evidence for precision immunotherapy approaches.
Enhanced Efficacy Through CIK Cell Combination
Preclinical research has demonstrated that combining dual checkpoint inhibitors with cytokine-induced killer (CIK) cells can significantly enhance anti-tumor effects. In vitro studies using ovarian cancer (搜索) cell lines A2780 and SKOV3 showed that the triple combination of nivolumab, ipilimumab, and CIK cells achieved superior results compared to dual checkpoint blockade alone.
The combination treatment induced significant apoptosis in both cell lines (A2780: ~16% vs ~7% control; SKOV3: ~17% vs ~7% control, P < 0.001) and caused G1-phase cell cycle arrest, with G0/G1 accumulation increasing from 40% in controls to 55% with combination treatment. Additionally, the therapy substantially suppressed migration and invasion capabilities, with wound closure reduced to ~25% in A2780 cells and ~35% in SKOV3 cells compared to ~50% and ~70% in respective controls.
Challenges and Future Directions
Despite promising results, significant challenges remain in translating dual checkpoint inhibition to clinical practice in ovarian cancer (搜索). The disease's low mutational burden (1-3.5 mut/Mb) and limited mismatch repair deficiency/microsatellite instability-high status (5-15% of cases) continue to limit the applicability of immunotherapy to a small fraction of patients.
The Korean NCT03699449 trial highlighted safety concerns with dual checkpoint blockade, as the combination of durvalumab plus tremelimumab with chemotherapy demonstrated grade 3/4 treatment-related adverse events in 66.7% of patients, substantially higher than other treatment groups (20%-47.1%).
Future therapeutic advancements will require strategic combinations designed to reverse immunosuppression and trigger robust anti-tumor immunity. The synergy between ICIs and PARP inhibitors extends beyond simple cytotoxicity, with evidence suggesting that PARP inhibitors can upregulate PD-L1 (搜索) expression on tumor cells and activate the cGAS-STING pathway, promoting type I interferon production and converting immunologically "cold" tumors into "hot" ones.
Precision Medicine Approach Needed
The profound heterogeneity of ovarian cancer (搜索) demands a paradigm shift toward precision medicine. Future biomarker development should encompass immunohistochemical profiling of tumor-infiltrating lymphocytes, genomic and transcriptomic signatures including tumor mutational burden and BRCA1/2 mutational status, and advanced integrative analytics leveraging machine learning algorithms to synthesize disparate data streams.
The next generation of clinical trials must be prospectively designed with the dual objective of evaluating rational drug combinations and rigorously validating sophisticated biomarker panels. This integrated strategy, coupling mechanistically grounded regimens with precision patient selection, is indispensable for unlocking the full therapeutic potential of dual checkpoint inhibition in ovarian cancer (搜索).